Drug Approval | December 21, 2024
USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The pooled prevalence of GERD in the Indian population is 15.6 %
Subscribe To Our Newsletter & Stay Updated
